Small

Zacks Small Cap Research – TELO Continues to Impress – Go Health Pro

by

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. … Read more

Zacks Small Cap Research – CTSO: CytoSorbents Reports Preliminary 4th Quarter and 2024 Financial Results Which Showed Impressive Product Revenue Growth That Exceeded Our Expectations. – Go Health Pro

by

By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On January 3, 2025, CytoSorbents (NASDAQ:CTSO) reported strong preliminary 4th quarter and full year 2024 financial results which exceeded our expectations. 4th quarter product revenue (excluding grant income) is estimated to be in the range of $9.0-$9.2 million, which is approximately 22% to 25% … Read more

Zacks Small Cap Research – AIRE: Positioning to Benefit From Expected Shift in Real Estate Transactions Model, Initiating Coverage – Go Health Pro

by
Zacks Small Cap Research – AIRE: Positioning to Benefit From Expected Shift in Real Estate Transactions Model, Initiating Coverage – Go Health Pro

By M. Marin NASDAQ:AIRE READ THE FULL AIRE RESEARCH REPORT Positioning commission free real estate technology platform to benefit from expected dramatic shift within real estate sector reAlpha Tech Corp. (NASDAQ:AIRE) is a real estate technology company that is developing an end-to-end commission-free homebuying platform. The reAlpha platform leverages artificial intelligence (AI) technologies in the … Read more

Zacks Small Cap Research – SCLX Gets Exclusive Rights to Important Drug – Go Health Pro

by

By Brad Sorensen, CFA NASDAQ:SCLX READ THE FULL SCLX RESEARCH REPORT Scilex Holding Company (NASDAQ:SCLX) is a revenue-generating company that is focused on addressing one of the biggest issues facing humanity today—that of the overuse of opioids. Scilex is focused on developing non-opioid pain management products that provide the relief patients so desperately need, while … Read more

Zacks Small Cap Research – LGND: 2025 View Calls for 17% Topline Growth – Go Health Pro

by
Zacks Small Cap Research – LGND: 2025 View Calls for 17% Topline Growth – Go Health Pro

By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) held its annual analyst day on December 10th, 2024 in Boston. The company provided its 2025 expectations calling for topline revenues of $180 to $200 million and core adjusted earnings per share (EPS) of $6.00 to $6.25. This represents an … Read more

x